Zevra Therapeutics (NASDAQ:ZVRA) Releases Earnings Results, Beats Estimates By $0.14 EPS

Zevra Therapeutics (NASDAQ:ZVRA) released its quarterly earnings data on Monday. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.05 by $0.14, FiscalAI reports. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The firm had revenue of $34.13 million for the quarter, compared to the consensus estimate of $28.05 million.

Zevra Therapeutics Trading Up 1.6%

Shares of ZVRA stock traded up $0.14 during mid-day trading on Monday, reaching $9.12. The stock had a trading volume of 990,773 shares, compared to its average volume of 861,176. The firm has a market capitalization of $513.44 million, a PE ratio of 19.40 and a beta of 0.91. The stock’s 50-day moving average price is $8.80 and its two-hundred day moving average price is $9.07. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16.

Insider Activity

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 91,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at $3,417,603. This represents a 19.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total value of $27,540.00. Following the completion of the sale, the senior vice president owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. This trade represents a 9.21% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 114,158 shares of company stock valued at $1,062,878. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after buying an additional 1,812 shares during the period. Strs Ohio bought a new position in shares of Zevra Therapeutics in the 1st quarter worth about $125,000. Creative Planning purchased a new position in Zevra Therapeutics during the 2nd quarter valued at about $92,000. Rhumbline Advisers lifted its position in Zevra Therapeutics by 11.6% during the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock valued at $733,000 after acquiring an additional 8,636 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Zevra Therapeutics during the second quarter worth about $255,000. Institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

ZVRA has been the subject of several analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research report on Tuesday, December 30th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.